



3
09/833,914
6696.US.O2
Rest. Resp.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Schrimpf, et al.

Serial No.: 09/833,914

Filed: April 12, 2001

For: DIAZABICYCLIC CENTRAL
NERVOUS SYSTEM ACTIVE
AGENTS

Examiner: B. L. Coleman

Group Art Unit: 1624

Case No.: 6696.US.O2

Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING (37 CFR
1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: September 23, 2002

Tanya Parent 9/23/02
Tanya Parent Date

TECH CENTER 1600/2900

OCT 07 2002

RECEIVED
H B PGS
10-9-02

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

The following is in response to the Office Action dated June 24, 2002, having a period of response through September 24, 2002 pursuant to a two-month extension of time in accordance with 37 C.F.R. § 1.136(a). Reconsideration is respectfully requested.

REMARKS

Claims 1-79 are subject to an election/restriction requirement. Applicants respectfully traverse the requirement.

Applicants respectfully elect Group III, including claims 1 and 2, in part, 27-40, and 71-79. Examination is therefore directed to compounds of formula IV, compositions thereof, and methods of using the same. Compounds of formula IV correspond to the compounds of formula I in claim 1, wherein A is -CH₂-, B is -CH₂-, and Y, Z, and R₁-R₉ are as defined in claim 1. Applicants elect as their species for searching purposes (cis)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane.